Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients
Treating critically ill COVID-19 patients with drugs typically used for rheumatoid arthritis may significantly improve survival, a landmark study has found. The findings, which were announced in January and have now been peer-reviewed and published in the New England Journal of Medicine, come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU). (Source: World Pharma News)
Source: World Pharma News - February 26, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. (Source: World Pharma News)
Source: World Pharma News - February 25, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Real-world effectiveness of COVID-19 vaccine
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the effectiveness of the Pfizer vaccine against COVID-19. The study provides the first large-scale peer-reviewed evaluation of the effectiveness of a COVID-19 vaccine in a nationwide mass-vaccination setting. The study was conducted in Israel, which currently leads the world in COVID-19 vaccination rates. (Source: World Pharma News)
Source: World Pharma News - February 25, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
Sanofi and GlaxoSmithKline (GSK) announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. (Source: World Pharma News)
Source: World Pharma News - February 24, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Researchers reveal genetic predisposition to severe COVID-19
HSE University researchers have become the first in the world to discover genetic predisposition to severe COVID-19. The results of the study were published in the journal Frontiers in Immunology. T-cell immunity is one of the key mechanisms used by the human body to fight virus infections. The staging ground for cell immunity development is the presentation of virus peptides on the surface of infected cells. (Source: World Pharma News)
Source: World Pharma News - February 23, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
Sanofi has entered into an agreement with Janssen Pharmaceutical NV and Janssen Pharmaceuticals, Inc., two of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which Sanofi will support manufacturing of Janssen's COVID-19 vaccine in order to address the COVID-19 pandemic and supply needs. Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization for its single-dose Janssen COVID-19 vaccine candidate and an application for conditional marketing authorisation to the European Medicines Agency. (Source: World Pharma News)
Source: World Pharma News - February 23, 2021 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Researchers discover potential new therapeutic targets on SARS-CoV-2 Spike protein
The COVID-19 pandemic has prompted considerable investigation into how the SARS-CoV-2 Spike protein attaches to a human cell during the infection process, as this knowledge is useful in designing vaccines and therapeutics. Now, a team of scientists has discovered additional locations on the Spike protein that may not only help to explain how certain mutations make emerging variants more infectious but also could be used as additional targets for therapeutic intervention. (Source: World Pharma News)
Source: World Pharma News - February 22, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of investigational single-shot Janssen COVID-19 vaccine candidate
Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. (Source: World Pharma News)
Source: World Pharma News - February 22, 2021 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses. The expanded collaboration, which builds on the agreement signed in 2020 to research and develop therapies for coronaviruses, (Source: World Pharma News)
Source: World Pharma News - February 19, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Antibody response may drive COVID-19 outcomes
COVID-19, the source of the current pandemic, may be caused by a single virus, but it has a variety of presentations that make treatment difficult. Children, for example, almost exclusively experience mild or asymptomatic COVID-19, while adults can develop severe or even fatal COVID-19. (Source: World Pharma News)
Source: World Pharma News - February 18, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech commence global clinical trial to evaluate COVID-19 vaccine in pregnant women
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in preventing COVID-19 in healthy pregnant women 18 years of age and older. (Source: World Pharma News)
Source: World Pharma News - February 18, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

European Commission purchases additional 150 million doses of COVID-19 vaccine Moderna
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an additional 150 million doses of the COVID-19 Vaccine Moderna, which are scheduled to be delivered in the third and fourth quarter of 2021. (Source: World Pharma News)
Source: World Pharma News - February 17, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Could a nasal spray prevent coronavirus transmission?
A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the nasal spray also may prevent infection in people exposed to the new coronavirus, including recent variants. (Source: World Pharma News)
Source: World Pharma News - February 17, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Neandertal gene variants both increase and decrease the risk for severe COVID-19
Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk factor for severe COVID-19 is inherited from Neandertals. Now the same researchers show, in a study published in PNAS, that Neandertals also contributed a protective variant. Half of all people outside Africa carry a Neandertal gene variant that reduces the risk of needing intensive care for COVID-19 by 20 percent. (Source: World Pharma News)
Source: World Pharma News - February 16, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization
AstraZeneca's COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunisation to prevent COVID-19 in individuals 18 years of age and older, including those over 65. (Source: World Pharma News)
Source: World Pharma News - February 16, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

A machine-learning approach to finding treatment options for COVID-19
When the COVID-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes forever," says Caroline Uhler, a computational biologist in MIT's Department of Electrical Engineering and Computer Science and the Institute for Data, Systems and Society, and an associate member of the Broad Institute of MIT and Harvard. (Source: World Pharma News)
Source: World Pharma News - February 15, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

U.S. government purchases additional 100 million doses of Moderna's COVID-19 vaccine
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the U.S. government has purchased an additional 100 million doses of Moderna's COVID-19 Vaccine, bringing its confirmed order commitment to 300 million doses. (Source: World Pharma News)
Source: World Pharma News - February 15, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

CureVac initiates rolling submission with European Medicines Agency for COVID-19 vaccine candidate, CVnCoV
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, the company's mRNA-based COVID-19 vaccine candidate, currently in late-stage clinical testing. (Source: World Pharma News)
Source: World Pharma News - February 12, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Sinovac receives conditional marketing authorization in China for its COVID-19 vaccine
Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac, Sinovac’s COVID-19 vaccine in individuals aged 18 and above. (Source: World Pharma News)
Source: World Pharma News - February 11, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

One dose of COVID-19 vaccine provokes strong immune response in those previously infected
Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those previously infected with SARS-CoV-2 is still not completely understood. Researchers from Bar-Ilan University and Ziv Medical Center now report preliminary evidence that people previously infected with the virus responded very strongly to one dose of the Pfizer vaccine, regardless of when they were infected and whether or not they had detectable antibodies against COVID-19 prior to receiving the vaccine. (Source: World Pharma News)
Source: World Pharma News - February 11, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
Novartis has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by supporting the production of the Pfizer-BioNTech COVID-19 Vaccine. The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland. (Source: World Pharma News)
Source: World Pharma News - February 10, 2021 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
Following the European Medicines Agency (EMA) approval, millions of AstraZeneca vaccines began shipping on 5 February as part of the initial 17m doses that are due to be delivered over the next weeks, with more planned in March. AstraZeneca and IDT Biologika are exploring options to accelerate output of finished COVID-19 Vaccine AstraZeneca in the second quarter of 2021 in order to help support Europe's immediate vaccination needs during the pandemic. (Source: World Pharma News)
Source: World Pharma News - February 10, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
As new COVID-19 variants begin to throw vaccine efficacy in question, two leading scientists are calling for health agencies to invest in the development of vaccines that would be broadly effective against many different variants and strains of potential pandemic viruses. In a commentary article published in the journal Nature, Dennis Burton, PhD, and Eric Topol, MD, of Scripps Research call for governments to provide significant funding support for rational vaccine design based on broadly neutralizing antibodies. (Source: World Pharma News)
Source: World Pharma News - February 9, 2021 Category: Pharmaceuticals Tags: Featured Events Source Type: news

FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19. (Source: World Pharma News)
Source: World Pharma News - February 9, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Anticancer drug may improve outcome for severe COVID-19 patients
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. (Source: World Pharma News)
Source: World Pharma News - February 8, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech publish data from in vitro studies demonstrating COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with key mutations present in U.K. and South African variants
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from individuals vaccinated with the Pfizer-BioNTech COVID-19 vaccine neutralize SARS-CoV-2 with key mutations present in the United Kingdom (U.K.) and South African variants. (Source: World Pharma News)
Source: World Pharma News - February 8, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Johnson & Johnson announces submission of application to the U.S. FDA for Emergency Use Authorization of its investigational single-shot Janssen COVID-19 vaccine candidate
Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. (Source: World Pharma News)
Source: World Pharma News - February 5, 2021 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries accepting the CE mark by mid-February 2021. In comparison to the existing Roche SARS-CoV-2 Rapid Antigen Test, the SARS-CoV-2 Rapid Antigen Test Nasal collects the sample from the front area of the nose instead of the nasopharynx, resulting in a simplified and faster testing procedure(1). (Source: World Pharma News)
Source: World Pharma News - February 4, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

GSK and CureVac to develop next generation mRNA COVID-19 vaccines
GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. (Source: World Pharma News)
Source: World Pharma News - February 4, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

How SARS-CoV-2 mutates to escape antibody binding
In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the University of Pittsburgh School of Medicine. Since these deletions happen in a part of the sequence that encodes for the shape of the spike protein, the formerly neutralizing antibody can't grab hold of the virus, the researchers report today in Science. (Source: World Pharma News)
Source: World Pharma News - February 3, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no hospitalisations, more than 22 days after the first dose. (Source: World Pharma News)
Source: World Pharma News - February 3, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Efficacy of Sputnik V against COVID-19 was reported at 91.6%
The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announce that The Lancet, one of the world's oldest and most respected medical journals, has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine's high efficacy and safety. Sputnik V, which is based on a well-studied human adenoviral vectors platform, is the world's first registered vaccine against coronavirus. (Source: World Pharma News)
Source: World Pharma News - February 2, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Bayer to manufacture mRNA vaccine in Germany
In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer of CureVac N.V., Franz-Werner Haas, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division, Stefan Oelrich, made the following statement: (Source: World Pharma News)
Source: World Pharma News - February 1, 2021 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Early functional SARS-COV-2 specific T cell response may prevent severe infection
Humoral and cellular adaptive immunity are two immune mechanisms that act against pathogens. Humoral immunity is mediated by antibodies, while cellular immunity does not involve antibodies and is, instead, facilitated by T cells. Studying how these immune mechanisms mediate SARS-CoV-2 infections could be beneficial in controlling the progression of the disease. (Source: World Pharma News)
Source: World Pharma News - February 1, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

COVID-19 Vaccine AstraZeneca recommended for use in the EU
AstraZeneca's COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. (Source: World Pharma News)
Source: World Pharma News - January 29, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

In vitro studies demonstrate Pfizer and BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with key mutations present in U.K. and South African variants
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from in vitro neutralization studies of sera from individuals vaccinated with the Pfizer-BioNTech COVID-19 vaccine. The sera neutralized SARS-CoV-2 with key mutations present in the United Kingdom (U.K.) and South Africa variants, as measured by studies conducted by Pfizer and the University of Texas Medical Branch (UTMB). (Source: World Pharma News)
Source: World Pharma News - January 28, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Valneva commences manufacturing of its inactivated, adjuvanted COVID-19 vaccine, completes Phase 1/2 study recruitment
Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in order to optimize the timeline for potential deliveries of the vaccine. The Phase 1/2 clinical study is now fully enrolled and is expected to report initial results in April 2021. (Source: World Pharma News)
Source: World Pharma News - January 28, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs
Sanofi and BioNTech have today entered into an agreement under which Sanofi will support manufacturing and supply of BioNTech’s COVID-19 vaccine which is being co-developed with Pfizer. Sanofi will provide BioNTech access to its established infrastructure and expertise to produce over 125 million doses of COVID-19 vaccine in Europe. Initial supplies will originate from Sanofi's production facilities in Frankfurt from summer of 2021. (Source: World Pharma News)
Source: World Pharma News - January 27, 2021 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Novel molecules to combat asthma and COVID-related lung diseases discovered
A study designed to study how the immune system impacts gut bacteria - has led to the extraordinary discovery of two molecules that can not only provide profound protection in experimental models of asthma but can also substantially reduce the severity of an attack. Neither of these molecules, one of which is already commercially available as a dietary supplement, were previously known to have an effect on asthma - and they also appear, from animal studies, to have a role in treating the respiratory illness that is prevalent, and often fatal, in people with serious COVID-19. (Source: World Pharma News)
Source: World Pharma News - January 26, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Merck discontinues development of SARS-CoV-2/COVID-19 vaccine candidates; continues development of two investigational therapeutic candidates
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. (Source: World Pharma News)
Source: World Pharma News - January 25, 2021 Category: Pharmaceuticals Tags: Featured Merck Business and Industry Source Type: news

COVAX announces new agreement, plans for first deliveries
COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, today announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO emergency use listing. Rollout will commence with the successful negotiation and execution of supply agreements. (Source: World Pharma News)
Source: World Pharma News - January 22, 2021 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial - conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN) - enrolled residents and staff at skilled nursing and assisted living facilities, commonly referred to as nursing homes, across the U.S. (Source: World Pharma News)
Source: World Pharma News - January 22, 2021 Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news

Obesity, impaired metabolic health and COVID-19
In a Nature Reviews Endocrinology article authors from the German Center for Diabetes Research (DZD) highlight the interconnection of obesity and impaired metabolic health with the severity of COVID-19. First, they provide information about the independent relationships of obesity, disproportionate fat distribution and impaired metabolic health with the severity of COVID-19. (Source: World Pharma News)
Source: World Pharma News - January 21, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known as B.1.1.7 lineage or VOC 202012/01. The results were published on the preprint server bioRxiv and submitted to a peer-reviewed journal. (Source: World Pharma News)
Source: World Pharma News - January 20, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
Roche (SIX: RO, ROG; OTCQX: RHHBY) confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of Regeneron's casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients as part of Operation Warp Speed. (Source: World Pharma News)
Source: World Pharma News - January 19, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

COVID-19 has multiple faces
According to current studies, the COVID-19 disease which is caused by the SARS-CoV-2 coronavirus comprises at least five different variants. These differ in how the immune system responds to the infection. Researchers from the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, together with other experts from Germany, Greece and the Netherlands, present these findings in the scientific journal "Genome Medicine". (Source: World Pharma News)
Source: World Pharma News - January 19, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Metformin use reduces risk of death for patients with COVID-19 and diabetes
Use of the diabetes drug metformin - before a diagnosis of COVID-19 - is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study at the University of Alabama at Birmingham. Diabetes is a significant comorbidity for COVID-19. (Source: World Pharma News)
Source: World Pharma News - January 18, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralising COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection. (Source: World Pharma News)
Source: World Pharma News - January 15, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

New England Journal of Medicine publishes COVID-19 treatment trial results
A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine. (Source: World Pharma News)
Source: World Pharma News - January 15, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bayer transforms pharma business through breakthrough innovation in healthcare
At its virtual Pharma Media Day, Bayer presented exciting progress in transforming its pharmaceutical business with breakthrough innovation in healthcare that will significantly help patients suffering from conditions that are currently still difficult to treat. The company has recently heavily invested in external innovation with an unprecedented number of more than 25 collaboration agreements and acquisitions. (Source: World Pharma News)
Source: World Pharma News - January 14, 2021 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news